Northeast Pharmaceutical Group Co., Ltd. (SHE:000597)
China flag China · Delayed Price · Currency is CNY
4.810
-0.030 (-0.62%)
Sep 10, 2026, 1:45 PM CST

SHE:000597 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
6,5297,0247,4488,1858,7198,046
Other Revenue
26.1850.8554.0958.5689.598.7
6,5557,0757,5038,2438,8098,145
Revenue Growth
-8.79%-5.70%-8.98%-6.42%8.15%10.30%
Cost of Revenue
4,2764,6454,7415,1255,5575,056
Gross Profit
2,2792,4302,7613,1183,2523,089
Selling, General & Admin
1,7441,9302,0962,5792,7672,698
Research & Development
168.34172.27117.7697.04160.3983.46
Other Operating Expenses
70.3570.0677.3481.7583.1383.86
Operating Expenses
1,9792,1722,2852,7523,0322,879
Operating Income
299.91258.22475.95366.2219.56210.63
Interest Expense
-25.09-49.16-64.53-78.36-92.11-120.16
Interest & Investment Income
49.3698.48133.79163.6993.88110.25
Currency Exchange Gain (Loss)
-20.74-25.8510.068.1128.68-6.45
Other Non Operating Income (Expenses)
-41.51-37.99-49.15-54.94-37.85-47.68
EBT Excluding Unusual Items
261.92243.7506.12404.7212.15146.59
Impairment of Goodwill
-1.04-1.04----
Gain (Loss) on Sale of Investments
0.350.35----
Gain (Loss) on Sale of Assets
1.291.056.190.17419.33.29
Asset Writedown
-74--10.12-3.9-7.97-28.96
Other Unusual Items
38.7761.291.7287.21-98.04-0.76
Pretax Income
227.29305.26593.91488.17525.44120.16
Income Tax Expense
69.9287.43170.63112.19168.2824.72
Earnings From Continuing Operations
157.37217.83423.28375.98357.1695.44
Minority Interest in Earnings
57.3942.24-13.43-17.52-6.93.59
Net Income
214.76260.07409.85358.46350.2599.03
Net Income to Common
214.76260.07409.85358.46350.2599.03
Net Income Growth
-43.81%-36.55%14.34%2.34%253.69%707.93%
Shares Outstanding (Basic)
1,4381,4451,4131,4341,4011,415
Shares Outstanding (Diluted)
1,4381,4451,4131,4341,4011,415
Shares Change
1.39%2.23%-1.43%2.34%-0.97%15.42%
EPS (Basic)
0.150.180.290.250.250.07
EPS (Diluted)
0.150.180.290.250.250.07
EPS Growth
-44.58%-37.93%16.00%0%257.14%600.00%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Free Cash Flow
848.441,009599.34351.32864.44626.7
Free Cash Flow Per Share
0.590.700.420.240.620.44
Dividend Per Share
0.0550.0550.1000.1000.1000.014
Dividend Growth
-45.00%-45.00%0%0%614.29%75.00%
Gross Margin
34.77%34.35%36.81%37.83%36.92%37.93%
Operating Margin
4.58%3.65%6.34%4.44%2.49%2.59%
Profit Margin
3.28%3.68%5.46%4.35%3.98%1.22%
Free Cash Flow Margin
12.94%14.26%7.99%4.26%9.81%7.69%
EBITDA
776.72767.861,025911.39754.38722.45
EBITDA Margin
11.85%10.85%13.67%11.06%8.56%8.87%
D&A For EBITDA
476.81509.63549.5545.19534.82511.82
EBIT
299.91258.22475.95366.2219.56210.63
EBIT Margin
4.58%3.65%6.34%4.44%2.49%2.59%
Effective Tax Rate
30.76%28.64%28.73%22.98%32.03%20.57%
Revenue as Reported
3,2227,0757,5038,2438,8098,145
Advertising Expenses
----7.1310.53